<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03708887</url>
  </required_header>
  <id_info>
    <org_study_id>RCT-N3</org_study_id>
    <nct_id>NCT03708887</nct_id>
  </id_info>
  <brief_title>The Effect of Omega-3 FA on Glucose and Lipid Homeostasis Disorders in Obese/Diabetic Patients</brief_title>
  <official_title>Double-blind and Placebo-controlled Study on Intervention Effect of n-3 Fatty Acids on Glucose and Lipid Homeostasis Disorders in Obese/Diabetic Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind and placebo-controlled study was conducted in current human study.

      The purpose of this study is to investigate the effects of n-3 PUFA intervention on glucose
      and lipid homeostasis in Chinese diabetic/obese patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 450 obese and 450 diabetic patients will be enrolled from Lanxi in China. They
      will be randomly assigned into one of the following three groups: Omega-3 fatty acids
      capsules (1 g/d); or omega-3 fatty acids capsules (3 g/d); or placebo capsules. Blood, feces
      and urine samples will be collected before and after treatment. Glucose and lipid parameters
      will be measured.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood glucose from baseline</measure>
    <time_frame>12 months</time_frame>
    <description>The investigators will measure HbA1c and fasting plasma glucose levels in blood samples before and after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood lipids from baseline</measure>
    <time_frame>12 months</time_frame>
    <description>The investigators will measure Triglycerides (TG), total cholesterol (TC), LDL-C, and HDL-C levels in blood samples before and after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in gut microbiota from baseline</measure>
    <time_frame>12 months</time_frame>
    <description>The investigators will collect faeces sample from every participants and 16S rDNA sequencing will be used to analyze the composition of gut microbiota.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Hyperglycaemia (Diabetic)</condition>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose omega-3 fatty acid supplementation, omega-3 fatty acids capsules, 1 gram per day for 1 year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose omega-3 fatty acid supplementation, omega-3 fatty acids capsules, 3 gram per day for 1 year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control drug, matching placebo capsules, 1 gram per day for 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose omega-3 fatty acid supplementation</intervention_name>
    <description>Omega-3 fatty acids capsules, 1 g/d by mouth for 1 year</description>
    <arm_group_label>Low dose group</arm_group_label>
    <other_name>Fish oil supplement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose omega-3 fatty acid supplementation</intervention_name>
    <description>Omega-3 fatty acids capsules, 3 g/d by mouth for 1 year</description>
    <arm_group_label>High dose group</arm_group_label>
    <other_name>Fish oil supplement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control drug</intervention_name>
    <description>Matching placebo capsules,1 g/d by mouth for 1 year</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Placebo drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed type 2 diabetes for diabetic groups according to WHO (1999) diagnostic
             criteria;

          -  BMI≥24 for obese/overweight groups;

          -  Aged between 50 and 70 years.

        Exclusion Criteria:

          -  TG≥4.56 mmol/L;

          -  Proliferative retinopathy;

          -  Pregnancy or lactation;

          -  Allergy to fish;

          -  Taking insulin;

          -  Premenopausal or menopause within 6 months;

          -  Have participated in other clinical trials in the last three months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jingjing Jiao, PHD</last_name>
    <phone>86-571-88982559</phone>
    <email>jingjingjiao@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yu Zhang, PHD</last_name>
    <email>y_zhang@zju.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lanxi Red Cross Hospital</name>
      <address>
        <city>Jinhua</city>
        <state>Zhejiang</state>
        <zip>321102</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weifang Zheng, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yu Zhang, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 14, 2018</study_first_submitted>
  <study_first_submitted_qc>October 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>October 14, 2018</last_update_submitted>
  <last_update_submitted_qc>October 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Jingjing Jiao</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Obesity</keyword>
  <keyword>Omega-3 fatty acids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

